Zimmer Adds to Board

Zimmer Holdings Inc. has named Michael J. Farrell, CEO of ResMed Inc., to its board of directors.

Farrell has served as CEO and a member of the board of directors of ResMed since March 2013. ResMed has corporate headquarters in San Diego, Calif., and its principal manufacturing facilities, as well as research and development facilities, in Sydney, Australia. The company developments medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing, chronic obstructive pulmonary disease and other chronic diseases.

Prior to his role as CEO, Farrell served as president of the Americas sector of ResMed from 2011 to 2013 and as senior vice president of the global sleep apnea business unit from 2007 to 2011. Before that, he held positions of increasing responsibility in marketing and business development.

“We are extremely pleased to welcome Mick Farrell to Zimmer’s board of directors,” said Larry Glasscock, chairman of the board. “His experience bringing innovative technologies to the global healthcare market will be a significant asset.”

Prior to joining ResMed in 2000, Farrell worked in management consulting and biotechnology, as well as in chemicals and metals manufacturing, at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company and BHP Billiton.

Farrell holds a bachelor of engineering from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management. In addition to the ResMed board, Farrell currently sits on the boards of directors of the Medical Device Manufacturers Association in Washington, D.C., and the California Healthcare Institute.

Warsaw, Ind.-based Zimmer makes orthopedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. The company’s 2013 sales were approximately $4.6 billion.